China's successful anti
As China with independent intellectual property rights Kangyi Yao objects "Aibo Wei-tai" in Phase I clinical trial is successful, is expected to fill the blank-AIDS drugs.
China successful clinical trials against AI (HC Pharmacy Industrial network with map)
Before the UN General Assembly Miguel d'Escoto Brockmann and UN Secretary General Ban Ki-moon at the United Nations 63rd General Assembly session a joint appeal, governments in the current economic crisis, should continue to ensure adequate funds for the fight AIDS . Relevant United Nations report states that to achieve by 2010, HIV infection were all treated the goal, the international community need to invest 25 billion U.S. dollars.
Data show that anti-AIDS drugs are rapidly expanding market size, annual sales growth rate of AIDS drugs is about 13% to 15%. At present, the use of 20 types of Chinese anti-AIDS drugs are imitations, there is no intellectual property rights of Chinese medicines. However, as China with independent intellectual property rights Kangai Yao objects "Aibo Wei-tai" in Phase I clinical trial is successful, is expected to fill the gaps.
Drug 2 Years after listing "Unlike in the past, this clinical trial in patients with direct access to the trial stage." R & D "Aibo Wei Tai" Frontier Biotechnology Co., Ltd. Chongqing official said, typically, the drug I clinical trials must first in Health Expand the human body, then the pilot phase of re-entry patients. But given the drug a good technical level, the National Science and Technology in consultation with relevant government departments to allow the drug directly to patient testing, thereby reducing the "Aibo Wei Tai" into the clinical trial period.
According to reports, as the national "863 Program", Chongqing City, the support of major research programs achieved significant Drug Discovery R & D results, "Aibo Wei Tai" is a membrane protein gp41 HIV-1 as the target design, by chemical synthesis and modification by the world's first long-acting anti-Ai drugs, and has listed drugs and medicines in the research than it has the advantage of the new role of chemical structure and characteristics. Test said, "Aibo Wei Tai" different places around the world HIV virus (Including the known resistance to the virus) has strong inhibitory effect, and no significant toxicity, drug half-life was significantly prolonged, treatment costs will be significantly reduced, and overall target has been exceeded in the international market, including permitted use with T20 various anti-HIV drugs, was a highly promising domestic and foreign experts agree the future development of new Drugs Species.
"By more than 1 year of clinical trials, 28 tests have not been found Adverse reactions . "In Beijing You'an Hospital And Ditan Hospital to start clinical trials showed that 28 tests in the injection of "Aibo Wei Tai" well after the injection, without any Adverse reactions . At the same time, than for the existing drugs, the drug's most important feature is the use of cycle interval length, thereby reducing the probability of occurrence of drug resistance in patients. In addition, after treatment of AIDS patients prone to liver disease, central nervous system diseases such as side effects, the drug also has significant mitigation effect.
Present, "Aibo Wei Tai" has been the concern of a number of multinational pharmaceutical companies. At the same time, the product has completed a Chinese invention patents and the PCT countries the United States and two international patent applications and has been patented European and Asian countries and New Zealand. Early in development, "Aibo Wei Tai" in access to the Ministry of Science and the "863 Project" Research Fund to support AIDS drugs, it is also the Chongqing Municipal Government, Municipal Science and Technology Commission, the United States in the ancient yo Institutes of Health, the Gates Foundation subordinate GMP's funds and other related support.
As "Aibo Wei-tai" I clinical trial is successful, the next two years, the drug will gradually end and clinical trials, is expected to mass production by 2011, widely used in clinical treatment of AIDS . However, market analysts pointed out that Kang Yiyao product market potential, almost all of the current reporting Kangai Yao goods sector can be Drug Administration "fast approval," but manufacturers such as cutting-edge biotechnology is still very few. The same time, Kang Yiyao materials R & D investment is higher, and higher technical requirements, which no relevant experience for the past Enterprise Speaking, not a reference, therefore, Kangai Yao Localization of matter when the road access to the corresponding profit remains to be seen.
I am China Crafts Suppliers writer, reports some information about performance aluminum radiator , performance silicone hose.
Processing your request, Please wait....
